ライフサイエンスコーパス: rem

1 e dose equivalent was 0.0106 mSv/MBq (0.0392 rem/mCi).

2 the effective dose to 0.0149 mSv/MBq (0.0551 rem/mCi) or 0.0171 mSv/MBq (0.0634 rem/mCi), respectivel

3 the effective dose was 0.016 mSv/MBq (0.058 rem/mCi).

4 q (0.0551 rem/mCi) or 0.0171 mSv/MBq (0.0634 rem/mCi), respectively.

5 ive dose equivalent was 0.018 mSv/MBq (0.065 rem/mCi), and the effective dose was 0.016 mSv/MBq (0.05

6 ive dose equivalent was 0.018 mSv/MBq (0.068 rem/mCi).

7 mean effective dose was 0.019 mSv/MBq (0.072 rem/mCi).

8 nistered activity was 0.0199 mSv/MBq (0.0735 rem/mCi.)

9 ; the effective dose is 0.022 mSv/MBq (0.083 rem/mCi).

10 The effective dose was 0.025 mSv/MBq (0.0922 rem/mCi).

11 ant effective dose was 28.79 muGy/MBq (0.107 rem/mCi).

12 n effective dose of (18)F-FPPRGD2 was 0.1462 rem/mCi +/- 0.0669 (0.0396 mSv/MBq +/- 0.0181).

13 wed by the heart wall at 0.048 mSv/MBq (0.18 rem/mCi).

14 dose of 2.01 x 10(-2) mSv/MBq (7.43 x 10(-2) rem/mCi).

15 dose was the kidneys at 0.066 mSv/MBq (0.24 rem/mCi), followed by the heart wall at 0.048 mSv/MBq (0

16 iding model) and uptake in the spleen (0.250 rem/mCi +/- 0.168 [0.068 mSv/MBq +/- 0.046]) and large i

17 ffective dose for men would be 2.6 mSv (0.26 rem), with a liver dose of 15.6 mSv (1.56 rem).

18 to an estimated effective dose of 3 mSv (0.3 rem) and an estimated dose to the target organ or tissue

19 ective dose for women would be 3.1 mSv (0.31 rem), with a liver dose of 17.1 mSv (1.7 rem); the effec

20 primary clearance through the kidneys (0.360 rem/mCi +/- 0.185 [0.098 mSv/MBq +/- 0.050]) and bladder

21 xposed to an effective radiation dose of 1.5 rem (15 mSv).

22 with an effective dose of 0.41 mSv/MBq (1.5 rem/mCi).

23 due to balloon rupture was estimated to be 5 rem/50 mCi treatment activity and compared favorably wit

24 -NPA yields an organ dose of under 50 mSv (5 rem) to all organs.

25 v/MBq +/- 0.046]) and large intestine (0.529 rem/mCi +/- 0.236 [0.143 mSv/MBq +/- 0.064]).

26 26 rem), with a liver dose of 15.6 mSv (1.56 rem).

27 n effective dose equivalent of 5.9 mSv (0.59 rem) and a lung dose of 21.8 mGy (2.18 rad) in young, he

28 his work is approximately 0.16 mSv/MBq (0.60 rem/mCi).

29 bladder wall (ca. 180 +/- 30 mSv/MBq or 0.7 rem/mCi with a 2.4 h void interval) suggests that multip

30 .31 rem), with a liver dose of 17.1 mSv (1.7 rem); the effective dose for men would be 2.6 mSv (0.26

31 compared favorably with that of (188)Re (78 rem/50 mCi).

32 0.098 mSv/MBq +/- 0.050]) and bladder (0.862 rem/mCi +/- 0.436 [0.233 mSv/MBq +/- 0.118], voiding mod

33 ix WWTPs range from 1.5 to 13.4 gCH(4)/kgCOD(rem), higher than those observed in previous studies usi

34 tion corresponding to an intron of the viral rem accessory gene, suggesting its derivation from splic

35 sponding to the processed mRNA for the viral rem gene; such Mtvs likely derive from spliced viral mRN

36 MTV-infected cells or cells transfected with rem or env cDNAs express SP, which is the active compone